Amneal Pharmaceuticals, Inc. (AMRX) Stock Price & Analysis

Amneal Pharmaceuticals, Inc. (AMRX) fell 2.41% to USD 17.44 as of September 8, 2026 at 06:24 UTC, according to Nexqual real-time market data.

AMRX last closed at USD 17.44; the session ranged USD 17.38–17.71 on volume of 1,440,974 shares. Market capitalization is —, with a 52-week range of USD 9.49–19.26 (NMS). Source: Nexqual, September 8, 2026 at 06:24 UTC.

Key Statistics (as of September 8, 2026 at 06:24 UTC)

Technical Analysis (AMRX)

Nexqual's technical model rates AMRX "SELL" based on 2 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 06:24 UTC.

From Amneal Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)

Key Strengths & Strategy (as disclosed to the SEC)

• By focusing on our high-value products with complex dosage forms and high barriers-to-entry, as well as taking advantage of our vertically integrated supply chain and selective use of internal API, we aim to manufacture more profitable products relative to our competition.
• The agreement also grants the Company an exclusive license to commercialize certain Metsera products in select emerging markets, including India, certain Southeast Asian countries, Africa, and the Middle East.
• ONGENTYS ® is BIAL's proprietary, once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor approved by the FDA in 2020 as an add-on treatment to carbidopa/levodopa in patients with Parkinson's disease experiencing "off" episodes.
• Generic pharmaceutical products have the same API, dosage form, strength, route of administration, and conditions of use as patented branded pharmaceutical products, are bioequivalent to the brand it copies, and are usually marketed under their chemical (generic) names rather than brand names.

Partnerships

• License Agreement with Zambon Biotech On February 23, 2024, we entered into a license, distribution and supply agreement with Zambon Biotech S.A. ("Zambon") granting Zambon the exclusive rights to seek regulatory approval and commercialize IPX203 in Europe (the "Zambon License Agreement").
• License Agreement On January 24, 2024, we entered into a 15-year license, distribution and supply agreement with Knight Therapeutics International S.A. ("Knight") granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America (the "Knight License Agreement").

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:24 UTC. This page is informational and not investment advice.